A recent review in Clinical Advances in Hematology & Oncology spotlights promising developments in gastrointestinal oncology — especially for colorectal and pancreatic cancers, where late-stage diagnoses have long limited options. Highlights include fruquintinib for refractory metastatic CRC, the tucatinib + trastuzumab combination for HER2-positive CRC, and expanded uses for trifluridine-tipiracil in combination regimens.
Trending
- GI Grand Rounds lecture – GI 2.0: From Procedures to Pathways
- Gastroenterology Practice Economics: Benchmark 2026 (Jiro Health)
- Surgery Partners to be taken private by Bon Secours affiliate in $5.7 billion deal (Reuters)
- Guardant Health Applauds New Law Ensuring Access to Colorectal Cancer Screening Innovations with No Cost-Sharing for Pennsylvanians (Guardant Health)
- Genmab and Incyte Announce Clinical Trial Collaboration in Metastatic Colorectal Cancer (Genmab)
- Do Wearables in GI Care Provide Useful Data or Fuel Anxiety? (Medscape)
- APPs Poised to Level the Playing Field for Rural Patients With IBD (GI & Endoscopy News)
- Improve IBD bowel checks for early cancer detection, study finds (Eurekalert)
